Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy

PURPOSE: Hematotoxicity is a potentially dose-limiting adverse event in patients with metastasized castration-resistant prostate cancer (mCRPC) undergoing prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT). We aimed to identify clinical or PSMA-targeted imaging-derived para...

Descripción completa

Detalles Bibliográficos
Autores principales: Widjaja, Liam, Werner, Rudolf A., Ross, Tobias L., Bengel, Frank M., Derlin, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484194/
https://www.ncbi.nlm.nih.gov/pubmed/34041564
http://dx.doi.org/10.1007/s00259-021-05412-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484194/
https://www.ncbi.nlm.nih.gov/pubmed/34041564
http://dx.doi.org/10.1007/s00259-021-05412-1

Ejemplares similares